Epacadostat with pre-op radiation for locally advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether adding epacadostat (a cancer drug) to standard pre-operative chemoradiation can improve outcomes for people with locally advanced rectal cancer. It’s designed to see if the added treatment is safe and potentially more effective before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (at least 18) with a new, confirmed diagnosis of locally advanced rectal cancer.
- Your cancer treatment plan includes short-course pre-op radiation (total neoadjuvant short course radiation), as your doctor intends.
- You have no prior rectal-cancer treatment (no previous anti-cancer therapy for rectal cancer).
- Your blood counts and key organs (liver, kidneys) are healthy enough for study treatment (specific lab cutoffs apply).
- You must be able to have study procedures, like tumor biopsies, if doctors find them safe and feasible at your site.
- If you could become pregnant or father a child, you must use effective birth control during the study and for 120 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This trial is testing a new drug combined with radiation and chemotherapy before surgery for locally advanced rectal cancer. The goal is to shrink the tumor and improve the chances of successful surgery.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
This trial compares a standard approach (chemotherapy and radiation before surgery) to a more intensive treatment (total neoadjuvant therapy plus radiation) for locally advanced rectal cancer. It aims to see if the stronger treatment helps remove the tumor and improves outcomes.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.